Hanmi Licenses Obesity Candidate HM17321 to Genentech
Hanmi Pharmaceutical granted Genentech exclusive rights outside Korea to develop, manufacture and commercialize the UCN2 analog HM17321 for obesity and related metabolic diseases.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Hanmi Pharmaceutical signed an exclusive licensing agreement with Roche subsidiary Genentech for HM17321, a non-incretin obesity drug candidate. The agreement covers rights outside Korea and also encompasses development for type 2 diabetes, cardiovascular disease and other related metabolic conditions.
A UCN2 approach to body composition
Hanmi Pharmaceutical designed HM17321 as a UCN2 analog intended to reduce body weight and fat while preserving muscle or increasing lean mass. This differentiates its proposed approach from incretin-based candidates such as GLP-1 and GIP drugs.
Clinical validation remains ahead
A Daol Investment & Securities analyst identified the planned 2027 Phase 1 trial as the key test of whether HM17321 can produce the intended body-composition changes in people. The candidate's weight-loss and muscle-related aims therefore should not be treated as established clinical outcomes at this stage.
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
